Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 103Lymphoma 68Lymphoma, Large B-Cell, Diffuse 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Sarcoma 33Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Leukemia 23Burkitt Lymphoma 22Neoplasms 19Lymphoma, Mantle-Cell 18Triple Negative Breast Neoplasms 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, B-Cell 14Lymphoma, Large-Cell, Anaplastic 12Carcinoma, Hepatocellular 12Breast Neoplasms, Male 11Neuroblastoma 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Inflammatory Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Peripheral 8Lymphoma, T-Cell 8Osteosarcoma 7Fallopian Tube Neoplasms 7Urinary Bladder Neoplasms 6Liposarcoma 6

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × PRETEXT I Hepatoblastoma × Doxorubicin × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡